iNtRON Biotechnology has announced that they have signed an “EVALUATION LICENSE AND OPTION AGREEMENT” with Basilea Pharmaceutica Ltd, Allschwil, granting Basilea the option to enter into an exclusive license agreement for the antibacterial bio-drug SAL200.
